Pramipexole in the treatment of refractory depression in a patient with rapid cycling bipolar disorder

Indian Journal of Psychological Medicine

Volumn 37, Issue 4, 2015, Pages 473-474

  Hegde, Aditya ^a   Singh, Aditi ^a   Ravi, Malvika ^a   Narayanaswamy, Janardhanan ^a   Math, Suresh ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949949726     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.168614     Document Type: Letter

References (5)

1. Vieta E, Valenti M. Pharmacological management of bipolar depression: Acute treatment, maintenance, and prophylaxis. CNS Drugs 2013;27:515-29
2. Citrome L. Treatment of bipolar depression: Making sensible decisions. CNS Spectr 2014;19 Suppl 1:1-12
3. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6
4. Mah L, Zarate CA Jr, Nugent AC, Singh JB, Manji HK, Drevets WC. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol 2011;14:545-51
5. Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. Pramipexole in treatment-resistant depression: A 16-week naturalistic study. Bipolar Disord 2002;4:307-14.